Therapeutic Area | MeSH |
---|---|
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MARINOL | Alkem Laboratories | N-018651 RX | 1985-05-31 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
dronabinol | NDA authorized generic | 2025-01-30 |
just cbd - cbd and thc ultra relief | C200263 | 2024-04-23 |
marinol | New Drug Application | 2023-02-14 |
syndros | New Drug Application | 2024-05-30 |
Code | Description |
---|---|
Q0167 | Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Marijuana abuse | D002189 | EFO_0007191 | F12 | 60 | 53 | 6 | 1 | 34 | 138 |
Cannabis | D002188 | — | — | 46 | 25 | 3 | 4 | 23 | 97 |
Pain | D010146 | EFO_0003843 | R52 | 14 | 13 | 23 | 1 | 2 | 51 |
Syndrome | D013577 | — | — | 15 | 22 | 9 | 1 | 12 | 49 |
Healthy volunteers/patients | — | — | — | 36 | — | — | 1 | 4 | 41 |
Sclerosis | D012598 | — | — | 1 | 7 | 25 | 1 | 1 | 32 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | 7 | 22 | 1 | 1 | 30 |
Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | 9 | 10 | 2 | 1 | 9 | 24 |
Muscle spasticity | D009128 | — | — | 2 | 5 | 13 | 1 | 1 | 20 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 4 | 6 | 1 | 2 | 3 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic pain | D059350 | — | — | 3 | 11 | 10 | — | 5 | 27 |
Neuralgia | D009437 | EFO_0009430 | — | 4 | 7 | 13 | — | 4 | 25 |
Neoplasms | D009369 | — | C80 | 7 | 7 | 9 | — | 3 | 22 |
Peripheral nervous system diseases | D010523 | — | G64 | 3 | 4 | 9 | — | — | 14 |
Back pain | D001416 | — | M54 | 1 | 5 | 8 | — | — | 13 |
Nausea | D009325 | — | R11.0 | 2 | 7 | 4 | — | 2 | 13 |
Marijuana use | D000074609 | — | — | 4 | 7 | 1 | — | 3 | 13 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 9 | 1 | — | — | 11 |
Dementia | D003704 | EFO_0003862 | F03 | 1 | 9 | 1 | — | 1 | 11 |
Psychomotor agitation | D011595 | — | — | 1 | 7 | 1 | — | 1 | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Substance-related disorders | D019966 | EFO_0003890 | F13 | 11 | 1 | — | — | 3 | 15 |
Driving under the influence | D000066448 | — | — | 6 | 3 | — | — | 3 | 11 |
Cognitive dysfunction | D060825 | — | G31.84 | 5 | 2 | — | — | 3 | 10 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 6 | — | — | 1 | 7 |
Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 3 | — | — | 1 | 7 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | 1 | — | — | 2 | 5 |
Alcoholic intoxication | D000435 | — | — | 3 | 1 | — | — | 2 | 5 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 2 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 4 | 4 | — | — | — | 5 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 2 | 3 | — | — | 1 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psychotic disorders | D011618 | — | F20.81 | 9 | — | — | — | 1 | 10 |
Pharmacokinetics | D010599 | — | — | 6 | — | — | — | 1 | 7 |
Adolescent behavior | D000294 | — | — | 1 | — | — | — | 2 | 3 |
Psychomotor disorders | D011596 | — | — | 2 | — | — | — | 1 | 3 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | 2 | — | — | — | 1 | 3 |
Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | 1 | 2 |
Magnetic resonance imaging | D008279 | — | — | 2 | — | — | — | — | 2 |
Psychological codependency | D017004 | — | — | 2 | — | — | — | — | 2 |
Renal insufficiency | D051437 | — | N19 | 2 | — | — | — | — | 2 |
Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 3 | 3 |
Leukocyte-adhesion deficiency syndrome | D018370 | EFO_1001359 | — | — | — | — | — | 3 | 3 |
Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 2 | 2 |
Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | — | 2 | 2 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
Adolescent development | D041923 | — | — | — | — | — | — | 2 | 2 |
Personality disorders | D010554 | — | F60.6 | — | — | — | — | 2 | 2 |
Fabry disease | D000795 | Orphanet_324 | E75.21 | — | — | — | — | 1 | 1 |
Paralysis | D010243 | — | — | — | — | — | — | 1 | 1 |
Adult children | D032721 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Dronabinol |
INN | dronabinol |
Description | Delta(9)-tetrahydrocannabinol is a diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. It has a role as a metabolite, a non-narcotic analgesic, a hallucinogen, a cannabinoid receptor agonist and an epitope. It is a diterpenoid, a benzochromene, a polyketide and a phytocannabinoid. |
Classification | Small molecule |
Drug class | cannabinol derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21 |
PDB | — |
CAS-ID | 1972-08-3 |
RxCUI | — |
ChEMBL ID | CHEMBL465 |
ChEBI ID | 66964 |
PubChem CID | 16078 |
DrugBank | DB00470 |
UNII ID | 7J8897W37S (ChemIDplus, GSRS) |